Methylene blue — The Mitochondrial Electron Carrier

Methylene blue functions as a redox cycler, auto-oxidizing in the presence of oxygen. It accepts electrons from NADH and transfers them directly to cytochrome c (Complex IV), bypassing Complexes I and III of the electron transport chain. This alternative electron transfer increases ATP synthesis and oxygen consumption while decreasing mitochondrial superoxide production. Additionally, it inhibits monoamine oxidase (MAO) and nitric oxide synthase (NOS), which contributes to its neuroprotective and vascular effects.

Methylene blue has been studied in human clinical trials primarily for neurodegenerative diseases and cognitive enhancement. A Phase 3 trial of a methylene blue derivative (LMTM) in Alzheimer's disease showed mixed results, failing to meet primary endpoints but suggesting potential benefits as a monotherapy. Other small human trials have demonstrated acute improvements in functional MR imaging and memory retrieval tasks, though robust, large-scale longevity trials are lacking.

In clinical and experimental settings for cognitive and mitochondrial support, low doses of 0.5 to 4 mg/kg per day are typically used. It is administered orally, often in divided doses. High doses (above 5 mg/kg) can have paradoxical pro-oxidant effects and are used for other medical indications like methemoglobinemia.

Methylene blue is generally well-tolerated at low doses but can cause dose-dependent adverse effects including gastrointestinal distress, dizziness, and blue discoloration of urine and sclera. It is a potent monoamine oxidase inhibitor (MAOI) and is strictly contraindicated with SSRIs, SNRIs, and other serotonergic drugs due to the risk of fatal serotonin syndrome. It should be avoided in individuals with G6PD deficiency due to the risk of severe hemolysis.

Key Papers